Paolo Scollo

Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial

Sandro Pignata, Giovanni Scambia, Gabriella Ferrandina et al. · Journal of Clinical Oncology · 2011 · 227 citations · Full text

Medicine, Oncology, Pharmacology +13

Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study

Marina Bagnoli, Silvana Canevari, Daniela Califano et al. · The Lancet Oncology · 2016 · 117 citations · Full text

Medicine, Bioinformatics, Oncology +16

Outcome and Risk Factors for Recurrence in Malignant Ovarian Germ Cell Tumors

Giorgia Mangili, Cristina Sigismondi, Angiolo Gadducci et al. · International Journal of Gynecological Cancer · 2011 · 113 citations

Medicine, Oncology, Surgery +17

Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial

Éric Pujade-Lauraine, Frédèric Selle, Giovanni Scambia et al. · Annals of Oncology · 2023 · 107 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome

Sabrina Chiara Cecere, Gaia Giannone, Vanda Salutari et al. · Gynecologic Oncology · 2019 · 106 citations · Full text

Medicine, Gynecology, Oncology +16